Sep 09, 2021 / 04:30PM GMT
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity Analyst
Thank you, everyone, for joining us today. I'm Drew Ranieri, a medical device analyst here at Morgan Stanley. It's my pleasure to have Adam Grossman, President and CEO; and Brian Lenz, EVP and CFO, from ADMA Biologics today.
Before we jump into Q&A, I just have to get the disclaimer out of the way first. But for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
With that out of the way, Adam, Brian, thanks so much for being with us today, looking forward to the conversation.
Questions and Answers:
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity AnalystAnd really as an observer of the company, it looks like there's been a tremendous amount of progress on both the commercial side and operationally over the last 12 months. So you've essentially spent kind of the last
Trustpilot
